BACKGROUND: The immunopathogenesis of chronic rhinosinusitis (CRS) is largely unknown, but it is thought that different inflammatory profiles are responsible for the different CRS subtypes. 25-Hydroxyvitamin-D (25-VD3) has been shown to alter inflammatory mediators in other disease processes and 25-VD3 deficiency is associated with CRS with nasal polyps (CRSwNP), but it is unknown if 25-VD3 levels impact local inflammation in CRS. This study investigated the correlation between plasma 25-VD3 and sinonasal mucus monocyte chemoattractant protein-1 (MCP-1), regulated upon activation normal T cell expressed and secreted (RANTES), and basic fibroblast growth factor (bFGF) levels in patients with CRS. METHODS: Study subjects undergoing endoscopic sinus surgery (ESS) for CRS were prospectively enrolled from January 2012 to August 2014. Control subjects included patients undergoing ESS for noninflammatory pathology. Blood and sinonasal mucus were collected at the time of ESS. Plasma 25-VD3 was measured by enzyme-linked immunosorbent assay (ELISA) and mucus levels of MCP-1, RANTES, and bFGF by cytometric bead array (CBA). RESULTS: A total of 57 patients were enrolled and categorized as CRS without nasal polyps (CRSsNP) (n = 31), CRSwNP (n = 14), and controls (n = 12). No significant correlation was found between MCP-1 and 25-VD3. There was a significant negative correlation between 25-VD3 and RANTES (r = -0.612; p = 0.026) and bFGF (r = -0.578; p = 0.039) in CRSwNP patients; however, there was no significant correlation in CRSsNP patients. CONCLUSION: This data suggests that 25-VD3 may play a role in regulation of RANTES and bFGF expression in CRSwNP. This may occur through regulation of NP fibroblasts or other immune cells. Further investigation is warranted to better elucidate the role of RANTES, bFGF, and 25-VD3 in CRSwNP.
BACKGROUND: The immunopathogenesis of chronic rhinosinusitis (CRS) is largely unknown, but it is thought that different inflammatory profiles are responsible for the different CRS subtypes. 25-Hydroxyvitamin-D (25-VD3) has been shown to alter inflammatory mediators in other disease processes and 25-VD3 deficiency is associated with CRS with nasal polyps (CRSwNP), but it is unknown if 25-VD3 levels impact local inflammation in CRS. This study investigated the correlation between plasma 25-VD3 and sinonasal mucus monocyte chemoattractant protein-1 (MCP-1), regulated upon activation normal T cell expressed and secreted (RANTES), and basic fibroblast growth factor (bFGF) levels in patients with CRS. METHODS: Study subjects undergoing endoscopic sinus surgery (ESS) for CRS were prospectively enrolled from January 2012 to August 2014. Control subjects included patients undergoing ESS for noninflammatory pathology. Blood and sinonasal mucus were collected at the time of ESS. Plasma 25-VD3 was measured by enzyme-linked immunosorbent assay (ELISA) and mucus levels of MCP-1, RANTES, and bFGF by cytometric bead array (CBA). RESULTS: A total of 57 patients were enrolled and categorized as CRS without nasal polyps (CRSsNP) (n = 31), CRSwNP (n = 14), and controls (n = 12). No significant correlation was found between MCP-1 and 25-VD3. There was a significant negative correlation between 25-VD3 and RANTES (r = -0.612; p = 0.026) and bFGF (r = -0.578; p = 0.039) in CRSwNP patients; however, there was no significant correlation in CRSsNP patients. CONCLUSION: This data suggests that 25-VD3 may play a role in regulation of RANTES and bFGF expression in CRSwNP. This may occur through regulation of NP fibroblasts or other immune cells. Further investigation is warranted to better elucidate the role of RANTES, bFGF, and 25-VD3 in CRSwNP.
Authors: Jennifer K Mulligan; David R White; Eric W Wang; S Ritter Sansoni; Helen Moses; Robert J Yawn; Carol Wagner; Sarah E Casey; Ryan M Mulligan; Rodney J Schlosser Journal: Otolaryngol Head Neck Surg Date: 2012-05-24 Impact factor: 3.497
Authors: Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald Journal: Rhinol Suppl Date: 2012-03
Authors: N Van Bruaene; Perez-Novo C; K Van Crombruggen; N De Ruyck; G Holtappels; P Van Cauwenberge; P Gevaert; C Bachert Journal: Clin Exp Allergy Date: 2012-06 Impact factor: 5.018
Authors: M Fraczek; B Rostkowska-Nadolska; D Kusmierz; A Zielinska; J Rok; E Sliupkas-Dyrda; A Grzanka; T Krecicki; M Latocha Journal: Adv Med Sci Date: 2012 Impact factor: 3.287
Authors: Tiffany K Gill; Catherine L Hill; E Michael Shanahan; Anne W Taylor; Sarah L Appleton; Janet F Grant; Zumin Shi; Eleonora Dal Grande; Kay Price; Robert J Adams Journal: BMC Public Health Date: 2014-09-26 Impact factor: 3.295
Authors: Zoë Urry; Emma S Chambers; Emmanuel Xystrakis; Sarah Dimeloe; David F Richards; Leona Gabryšová; Jillian Christensen; Atul Gupta; Sejal Saglani; Andrew Bush; Anne O'Garra; Zarin Brown; Catherine M Hawrylowicz Journal: Eur J Immunol Date: 2012-08-20 Impact factor: 5.532
Authors: Jennifer K Mulligan; Kunal Patel; Tucker Williamson; Nicholas Reaves; William Carroll; Sarah E Stephenson; Peng Gao; Richard R Drake; Benjamin A Neely; Stephen Tomlinson; Rodney J Schlosser; Carl Atkinson Journal: Mucosal Immunol Date: 2018-06-15 Impact factor: 7.313